Fennec Pharmaceuticals Inc. (TSE:FRX) insider S.P.A. Essetifin purchased 294,115 shares of the stock in a transaction dated Tuesday, December 12th. The stock was acquired at an average cost of C$8.50 per share, with a total value of C$2,499,977.50.

Fennec Pharmaceuticals Inc. (TSE FRX) traded up C$0.28 during trading hours on Thursday, reaching C$11.68. 2,425 shares of the company were exchanged, compared to its average volume of 4,580. Fennec Pharmaceuticals Inc. has a 12 month low of C$2.30 and a 12 month high of C$16.23.

Separately, Laidlaw initiated coverage on shares of Fennec Pharmaceuticals in a research report on Wednesday, November 29th. They issued a “buy” rating and a C$22.00 price target for the company.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/fennec-pharmaceuticals-inc-frx-insider-s-p-a-essetifin-purchases-294115-shares-of-stock/1764533.html.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.